Mayo clinic tests popular Weight-Loss drugs on stomach function

NCT ID NCT06801015

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study at Mayo Clinic compares two FDA-approved weight-loss drugs, semaglutide and tirzepatide, against a placebo to see how they affect stomach emptying and feelings of fullness. Thirty adults with obesity or overweight plus prediabetes will receive weekly injections for 24 weeks. Researchers will measure stomach function using special imaging and calorie intake tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Semaglutide and tirzepatide (weekly injections)

What this could lead to

If successful, this could help doctors understand how these weight-loss drugs work on the stomach, potentially improving treatment for obesity.

What could go wrong

This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The drugs are already approved, but this trial focuses on stomach function, not weight loss directly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States